Open Clinical Trials – Updated June 15, 2019

Immunotherapy AML ALL CLL Non-Hodgkins Lymphoma
Multiple Myeloma Transplant Post Transplant Supportive Care/Other
DiseaseTrial NumberName of TrialDrug & Link to clinicaltrials.gov
Immunotherapy
NSH1150Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High-Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell TransplantationPembrolizumab NCT02771197
NSH1206A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects with High-risk Diffuse Large B-cell Lymphoma Post-Autologous Hematopoietic Stem Cell TransplantationBlinatumomab NCT03298412
NSH 1210A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Loncastuximab Tesirine NCT03575351
CAR T-cell: NHLNSH1170A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma JCAR017 NCT02631044
NSH1207
A Global Randomized, Multicenter Phase 3 trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell non-Hodgkin lymphomas (TRANSFORM)JCAR017 NCT03575351
NSH 1230 (Open in July 2019)A Phase 2 study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL JCAR017 NCT03483103
CART-cell: CLL/Small Lymphocytic Lymphoma NSH1226 (Open in June 2019)An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma JCAR017 NCT03331198
CAR T-cell: Multiple MyelomaNSH1216A Phase 3, Multicenter, Randomized, Open-Lable Study to Compare the Efficacy and Safety of BB2121 versus Daratumumab(DARA) in Combination with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMM-3) bb2121 NCT03651128
AML
 NSH1150Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High-Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell TransplantationPembrolizumab NCT02771197
 NSH1169A Phase I/II Study of SEL24 in Patients with Acute Myeloid LeukemiaSel24 NCT03008187
 NSH1208A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies Vyxeos NCT03555955
 NSH1223A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Plexxikon NCT03787498
 C332 (Open June 2019)A Phase I Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia Ipilimumab NCT02890329
ALL
CLL
CLL
NSH1226 (Open in June 2019)
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma JCAR017
NCT03331198
Non-Hodgkins Lymphoma
 NSH1170A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma JCAR017 NCT02631044
NSH1206A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects with High-risk Diffuse Large B-cell Lymphoma Post-Autologous Hematopoietic Stem Cell TransplantationBlinatumomab NCT03298412
NSH1207
A Global Randomized, Multicenter Phase 3 trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-Cell non-Hodgkin lymphomas (TRANSFORM)JCAR017 NCT03575351
NSH 1210A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Loncastuximab Tesirine NCT03575351
NSH1226 (Open in June 2019)
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma JCAR017
NCT03331198
NSH 1230 (Open in July 2019)A Phase 2 study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL JCAR017 NCT03483103
C378 (Open July 2019)A Phase I trial of the combination of lenalidomide and blinatumomab in patients with relapsed/refractory NHL Lenalidomide/ Blinatumomab NCT02568553
C379 (Open July 2019)Randomized Phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive b-cell lymphomasCDZ-1127 Varlilumab NCT03038672
Multiple Myeloma
NSH1107A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy with the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-Risk Hematologic Malignancies.Bendamustine NCT02416206
NSH1216A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (rrMM) (KarMMa-3)CT03651128
 Transplant
C378 (Open July 2019)A Phase I trial of the combination of lenalidomide and blinatumomab in patients with relapsed/refractory NHL Lenalidomide/ Blinatumomab NCT02568553
C379 (Open July 2019)Randomized Phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive b-cell lymphomasCDZ-1127 Varlilumab NCT03038672
 Multiple MyelomaNSH1107A Phase II Trial of High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Upfront Treatment of Multiple MyelomaBendamustine
NCT02416206
AMLNSH1150Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High-Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell TransplantationPembrolizumab
NCT02771197
Aplastic AnemiaNSH1158A Study of T Cell Replete, HLA-Mismatched Bone Marrow Transplantation With Post-Transplant Cyclophosphamide as a Front-Line Therapy for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related DonorFludarabine
Cyclophos NCT02828592
Sickle Cell AnemiaNSH1184Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease NCT03263559
 Post Transplant
AMLNSH1182BMT CTN 1506 Randomized Trial of FLT3 Inhibitor vs Placebo as Maintenance Therapy Post Allogeneic TransplantGilteritinib NCT02997202
NHLNSH1206A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects with High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem Cell TransplantationBlinatumomab NCT03298412
Supportive Care/Other
NSH721NMDP Recipient Consent for Participation in Registry, Research Database, and Research Sample Repository NCT00495300 (sample)  NCT01166009 (database)
 NSH943A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other IndicationsNCT01351545
NSH995A Multicenter Safety Study of unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric
and Adult Patients
NCT01656603